Immunotherapy for lung metastases of murine renal cell carcinoma: Synergy between radiation and cytokine-producing tumor vaccines

Journal of Immunotherapy

Volumn 22, Issue 4, 1999, Pages 308-314

  Nishisaka, Nobuyasu ^a   Maini, Atul ^a   Kinoshita, Yoshihisa ^b   Yasumoto, Ryoji ^b   Kishimoto, Taketoshi ^b   Jones, Richard F ^a   Morse, Philo ^a   Hillman, Gilda G ^c   Wang, Ching Y ^a   Haas, Gabriel P ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Renal cell carcinoma Radiation therapy Vaccine therapy

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; KIDNEY CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUBCUTANEOUS TISSUE TUMOR; VACCINATION;

EID: 0032993030     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199907000-00004     Document Type: Article

References (49)

1. Sarah H, Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, CA Cancer J Clin 1998;48:6-29.
2. Haas GP, Hillman GG. Update on the role immunotherapy in the management of kidney cancer. Cancer Control 1996;3:66-71.
3. Harris DT. Hormonal therapy and chemotherapy of renal cell carcinoma. Semin Oncol 1983;10:422-30.
4. Yagoda A. Chemotherapy of renal cell carcinoma: 1983-1989. Semin Urol 1989;7:199-206.
5. Figlin RA, deKernion JB, Mukamel E, et al. Recombinant interferon-alpha-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol 1988;6:1604-10.
6. Muss HB. Renal cell carcinoma. In: DeVita VT, Heilman S, Rosenberg SA, ed. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:298-311.
7. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High dose recombinant IL-2 in the treatment of patients with disseminated cancer. Response, treatment-related morbidity and histologic findings. JAMA 1986;256:3117-24.
8. Sondel PM, Kohler PC, Hank JA, et al. Recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer: clinical and immunologic effects. Cancer Res 1988;48:2561-7.
9. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high dose interleukin 2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-84.
10. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for treatment macrophage of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
11. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
12. Fearon E, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 1990;60:397-403.
13. Patel PM, Flemming CL, Russell SJ, et al. Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumour. Br J Cancer 1993;68:295-302.
14. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-7.
15. Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-86.
16. Dougherty GJ, Thacker JD, Lavey RS, Belldegrun A, McBride WH. Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo. Cancer Immunol Immunother 1995;38:339-45.
17. Zitrogel L, Tahara H, Robbins PD, et al. Immunotherapy of established tumor with IL-12: effective delivery by genetically engineered fibroblasts. Am Assoc Immunol 1995;155:1393-403.
18. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expressing of mouse interferon-γ cDNA in neuroblastoma C1300 cells results in reduced tumorgenicity by augmented anti-tumour immunity. Proc Natl Acad Sci USA 1989;86:9456-60.
19. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gene-inserted tumor cells. J Immunol 1993;150:1458-70.
20. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocytecolonystimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
21. Blankenstein T, Qin Z, Uberla K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991;173:1047-52.
22. Teng MN, Park BH, Koeppen HK, Fendly BM, Schreiber H. Longterm inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 1991;88:3535-9.
23. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46.
24. Wakimoto H, Abe J, Nakamura Y, et al. Enhanced antitumor effects by vaccines and IL-2-secreting cytotoxic T lymphocytes. Gene Therapy. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1994:164.
25. Hollingsworth SJ, Darling D, Gaken J, et al. The effect of combined expression of interleukin 2 and interleukin 4 on tumorigenicity and treatment of B16F10 melanoma. Br J Cancer 1996;74:6-15.
26. Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-7 cDNAs. Blood 1994;83:1289-98.
27. Hillman GG, Haas GP. Role of cytokines in lymphocyte function. In: Aggarwal BB, Puri RK ed. Human cytokines. Their role in disease and therapy. Cambridge, Massachusetts: Blackwell Science, 1994:37-54.
28. Abe J, Wakimoto H, Tsunoda R, et al. In vivo anti-tumor effect of cytotoxic T lymphocytes engineered to produce interferon-7 by adenovirus-mediated genetic transduction. Biochem Biophys Res Commun 1996;218:164-70.
29. Hamada K, Tsunoda R, Hamada H. GM-CSF-induced in vivo expansion of splenic dendritic cells and their strong costimulation activity. J Leukoc Biol 1996;60:181-90.
30. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. Antitumor effect induced by granulocyte/macrophage-colonystimulating factor gene-modified tumor vaccination: comparison of adenovirus-and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 1995;121:587-92.
31. Younes E, Haas GP, Dezso B, et al. Local tumor irradiation augments the response to therapy in a murine renal adenocarcinoma. Cell Immunol 1995;165:243-51.
32. Hauser SH, Calorini L, Wazer DE, Gattoni-Celli S. Radiationenhanced expression of major histocompatibility complex class I antigen H-2D in B16 melanoma cells. Cancer Res 1993;53:1952-5.
33. Hareyama M, Imai K, Kubo K, et al. Effect of radiation on the expression of carcinoembryonic antigen of human gastric adenocarcinoma cells. Cancer 1991;67:2269-74.
34. Santin AD, Hiserodt JC, Fruehauf J, DiSaia PJ, Pecorelli S, Granger GA. Effects of irradiation on the expression of surface antigens in human ovarian cancer. Gyne Oncol 1996;60:468-74.
35. Younes E, Haas GP, Dezso B, et al. Radiation-induced effects on murine kidney tumor cells: role in the interaction of local irradiation and immunotherapy. J Urol 1995;153:2029-33.
36. Dezso B, Haas GP, Hamzavi F, et al. The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases. Clin Cancer Res 1996;2:1543-52.
37. Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 1990;18:5322.
38. Gansbacher B, Zier K, Cronin K, et al. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferongamma in irradiated human melanoma cells. Blood 1992;80:2817-25.
39. Visseren MJ, Koot M, van der Voort El, et al. Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity. J Immunother 1994;15:119-28.
40. Abdel-Wahab Z, Li WP, Osanto S, et al. Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell Immunol 1994;159:26-39.
41. Maass G, Schmidt W, Berger M, et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1995;92:5540-4.
42. Kinoshita Y, Nishisaka N, Kono T, Yasumoto R, Wada S, Kishimoto T. Cancer immunotherapy of established tumor with GM-CSF and IFN-r/IL-6 genetically modified tumor cells vaccination. Br J Urol 1997;80:528A.
43. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 1994;152:2324-32.
44. Park MW, Oliver W, Valinsky J, Schuler G, Steinman RM. Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 1987;166:1484-98.
45. Inaba K, Steinman RM, Park MW, et al. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 1992;175:1157-67.
46. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
47. Kinoshita Y, Nishisaka N, Kono T, Yokotani N, Yasumoto R, Kishimoto T. Immunotherapy of cancer with genetically modified tumor vaccine by combining GM-CSF and IL-6 genes. J Urol 1997;157:414A.
48. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JL, Bierer BE, Croop JM. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 1998;91:222-30.
49. Kos FJ, Erglemen EG. Immune regulation: a critical link between NK cells and CTLs. Immunol Today 1997;17:174-6.